Randomized double-blinded pilot clinical study of the antidiabetic activity of Balanites aegyptiaca and UPLC-ESI-MS/MS identification of its metabolites

Autor: Amira Abdel Motaal, Adel Hasheesh, Maha M. Salama, Shahira M. Ezzat, Hend Rashad, Fateheya M. Metwally
Jazyk: angličtina
Rok vydání: 2017
Předmět:
Blood Glucose
Male
0301 basic medicine
Pharmaceutical Science
Pilot Projects
Type 2 diabetes
Pharmacology
01 natural sciences
chemistry.chemical_compound
Tandem Mass Spectrometry
Drug Discovery
Balanites
Chromatography
High Pressure Liquid
Cross-Over Studies
biology
Traditional medicine
General Medicine
Middle Aged
antidiabetic activity
Molecular Medicine
Female
Balanites aegyptiaca
balanites aegyptiaca
Spectrometry
Mass
Electrospray Ionization
uplc profiling
Placebo
03 medical and health sciences
Double-Blind Method
Glucoside
Zygophyllaceae
In vivo
medicine
Humans
Hypoglycemic Agents
Plant Extracts
business.industry
010401 analytical chemistry
lcsh:RM1-950
clinical study
biology.organism_classification
medicine.disease
Sterol
0104 chemical sciences
030104 developmental biology
lcsh:Therapeutics. Pharmacology
Diabetes Mellitus
Type 2
Complementary and alternative medicine
chemistry
business
Body mass index
Zdroj: Pharmaceutical Biology, Vol 55, Iss 1, Pp 1954-1961 (2017)
ISSN: 1744-5116
1388-0209
Popis: Context:Balanites aegyptiaca Del. (Zygophyllaceae) fruits are traditionally known for the treatment of hyperglycaemia. Several in vitro and in vivo studies proposed some mechanisms of action. However, clinical trials in human beings were never reported to date. Objectives: To investigate the antidiabetic efficacy of the 70% ethanol extract of the pericarps of B. aegyptiaca (BE) within a nutritional intervention in elderly people. Materials and methods: Ultra-performance electrospray ionization-mass spectroscopy (UPLC-ESI-MS/MS) analysis was used for metabolic profiling of BE which was incorporated in hard gelatine capsules (400 mg/day) and tested on 30 type 2 diabetes (T2D) Egyptian patients for 8 weeks. According to sex, age and body mass index participants were divided into two equivalent groups, placebo and treatment. Results: Thirteen compounds were identified in BE using UPLC-ESI-MS/MS analysis among which five steroidal saponins, seven phenolic compounds and a sterol glucoside. At the end of the 8-week treatment, the treated group showed 26.88% decrease in 2 h postprandial plasma glucose relative to 2.6% increase in the placebo group, while fasting plasma glucose was reduced to 10.3%. Treatment with BE capsules for 8 weeks produced significant reduction in the plasma triglyceride, total cholesterol and low-density lipoprotein cholesterol by 9.0, 12.76 and 21.35%, respectively, with 29.8% increase in the high-density lipoprotein cholesterol. Plasma alanine transaminase and aspartate transaminase were reduced by 42.6 and 43.3%, respectively. Discussion and conclusion: Administration of the BE capsules to T2D resulted in significant improvements in the glycaemic markers and the lipid profile, without adverse effects or hypoglycaemia.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje